PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media
- Conditions
- Otitis Media
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00360100
- Locations
- 🇵🇦
Pfizer Investigational Site, Ciudad de Panama, Panama
Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater
- Conditions
- Optic Nerve Diseases
- Interventions
- Drug: Zyvox - linezolidDrug: Matched control
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00359632
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸Triple O Research Institute, PA, West Palm Beach, Florida, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1976
- Registration Number
- NCT00359801
- Locations
- 🇬🇧
Pfizer Investigational Site, Westbury, United Kingdom
Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.
- Conditions
- Heart Valve Diseases
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2007-09-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00359489
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia
- Conditions
- Pain
- First Posted Date
- 2006-07-28
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 246
- Registration Number
- NCT00357825
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Insulin lispro (Humalog)Drug: Inhaled Human Insulin (Exubera®)
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 58
- Registration Number
- NCT00356421
- Locations
- 🇬🇧
Pfizer Investigational Site, Birmingham, West Midlands, United Kingdom
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension
- Conditions
- HypertensionBlood Pressure, High
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00355589
- Locations
- 🇺🇸
Lovelace Scientific Resources, Sarasota, Florida, United States
🇺🇸Partners in Primary Care, Voorhees, New Jersey, United States
🇺🇸Medford Medical Clinic Research Dept., Medford, Oregon, United States
[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.
- Conditions
- Pain
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2007-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00354094
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.
- Conditions
- Pain
- Interventions
- Drug: [S,S]-Reboxetine
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 112
- Registration Number
- NCT00353808
- Locations
- 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States
A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061
- Conditions
- HIV-1
- Interventions
- Drug: UK-453,061
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2013-10-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 49
- Registration Number
- NCT00348673
- Locations
- 🇩🇪
Pfizer Investigational Site, Koeln, Germany